BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

71 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The present trial will be performed to determine the MTD and to evaluate the efficacy of BI 2536 in the treatment of elderly patients with relapsed or refractory AML. Different schedules will be compared to identify the better dosing schedule for the further development programme of BI 2536. Dose escalation starting with the maximum tolerated dose previously determined in patients with advanced solid cancers will be performed to determine the maximum tolerated dose for AML patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Trial to Find and Investigate a Safe Dose of BI 836858 in Combination With Decitabine for Patients With Acute Myeloid Leukemia (AML)

NCT02632721

Leukemia, Myeloid, Acute

COMPLETED PHASE1/PHASE2

BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)

NCT01296932

Leukemia, Lymphocytic, Chronic, B-Cell

COMPLETED PHASE1

A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies

NCT07107204

Relapsed or Refractory Hematologic Malignancies Leukemia Lymphoma +1 more

NOT_YET_RECRUITING PHASE1/PHASE2

Oral Clofarabine for Acute Myeloid Leukemia

NCT00727766

Leukemia, Myeloid, Acute

COMPLETED PHASE1

Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)

NCT01209286

B-ALL

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leukemia, Myeloid, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

BI 2536

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients older than 60 years of age
* Patient with confirmed AML (except for APL) according to the WHO definition who relapsed after or are refractory to prior chemotherapy
* Leukocyte count \<= 25,000 /mcl (25 x 10e9/Liter)
* Patient not eligible for intensive treatment options
* Life expectancy \>= 2 months
* Eastern co-operative oncology group performance score of 2 or less
* Signed written informed consent consistent with international conference on harmonisation - good clinical practice (ICH-GCP) and local legislation

Exclusion Criteria

* Patient with acute promyelocytic leukaemia (APL, AML of the French-American-British (FAB) classification subtype M3)
* Hypersensitivity to the trial drug or the excipients
* Secondary malignancy requiring therapy
* Known central nervous system involvement
* Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal, or AST or ALT greater than 5 times the upper limit of normal in case of known liver involvement
* Bilirubin greater than 1.5 mg/dl (\> 26 mcmol/l, SI unit equivalent)
* Serum creatinine greater than 2.0 mg/dl
* Concomitant intercurrent illness, which would compromise the evaluation of efficacy or safety of the trial drug, e.g. active severe infection, unstable angina pectoris or cardiac arrhythmia
* Psychiatric illness or social situation that would limit compliance with trial requirements
* Concomitant therapy, which is considered relevant for the evaluation of the efficacy or safety of the trial drug
* Chemotherapy (except hydroxyurea) or immunotherapy or treatment with any other investigational drug within the past four weeks prior to treatment with the trial drug
* Persistence of toxicities of prior anti-leukaemia therapies which are deemed to be clinically relevant
* Patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial (hormonal contraception, intrauterine device, condom with spermicide, etc.)
* Patient unable to comply with the protocol

Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No